Financial reports
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
28 Nov 23
10-K/A
2022 FY
Annual report (amended)
28 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
8 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
Current reports
8-K
Cyclacel Pharmaceuticals Reports fourth quarter and full year 2023 financial results and provides business update
19 Mar 24
8-K
Departure of Directors or Certain Officers
30 Jan 24
8-K
Other Events
12 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Other Events
4 Jan 24
8-K
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
26 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
12 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
28 Nov 23
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
15 Nov 23
8-K
Cyclacel Pharmaceuticals Reports THIRD quarter financial results
13 Nov 23
Registration and prospectus
S-1
IPO registration
25 Mar 24
424B3
Prospectus supplement
14 Feb 24
S-1/A
IPO registration (amended)
8 Feb 24
S-1
IPO registration
19 Jan 24
424B5
Prospectus supplement for primary offering
26 Dec 23
S-3
Shelf registration
1 Sep 23
S-8
Registration of securities for employees
24 Jul 23
S-8
Registration of securities for employees
11 Aug 22
424B5
Prospectus supplement for primary offering
30 Mar 22
S-8
Registration of securities for employees
19 Aug 21
Proxies
DEF 14A
Definitive proxy
14 Nov 23
PRE 14A
Preliminary proxy
2 Nov 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
26 Apr 22
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
29 Apr 21
DEFA14A
Additional proxy soliciting materials
12 May 20
DEF 14A
Definitive proxy
12 May 20
Other
EFFECT
Notice of effectiveness
14 Feb 24
CORRESP
Correspondence with SEC
12 Feb 24
CORRESP
Correspondence with SEC
7 Feb 24
UPLOAD
Letter from SEC
26 Jan 24
EFFECT
Notice of effectiveness
14 Sep 23
CORRESP
Correspondence with SEC
11 Sep 23
UPLOAD
Letter from SEC
7 Sep 23
EFFECT
Notice of effectiveness
21 Apr 20
CORRESP
Correspondence with SEC
16 Apr 20
UPLOAD
Letter from SEC
16 Mar 20
Ownership
SC 13G/A
Schonfeld Strategic Advisors LLC
14 Feb 24
SC 13G/A
Dellora Investments LP
14 Feb 24
SC 13G/A
Altium Capital Management LP
13 Feb 24
SC 13G/A
ACORN BIOVENTURES, L.P.
7 Feb 24
4
BRIAN SCHWARTZ
31 Jan 24
SC 13G
Altium Capital Management LP
10 Jan 24
SC 13G
Lind Global Fund II LP
4 Jan 24
4
Paul McBarron
26 Dec 23
4
Spiro George Rombotis
26 Dec 23
4
Spiro George Rombotis
3 Jul 23